AbCellera Biologics Inc.

Healthcare · Biotechnology · Canada

Last price 12.27 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.98B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lil...